Citigroup’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Citigroup’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,600	Closed	-$1.29M	–	7837
2020 Q3	$1.29M	Sell	11,600 -400	-3%	-$43K	﹤0.01%	3045
2020 Q2	$1.23M	Sell	12,000 -9,000	-43%	-$963K	﹤0.01%	3334
2020 Q1	$2.27M	Sell	21,000 -9,700	-32%	-$1.11M	﹤0.01%	2369
2019 Q4	$3.57M	Buy	30,700 +4,200	+16%	+$486K	﹤0.01%	2340
2019 Q3	$3.03M	Sell	26,500 -3,500	-12%	-$348K	﹤0.01%	2406
2019 Q2	$2.86M	Sell	30,000 -13,500	-31%	-$1.27M	﹤0.01%	2457
2019 Q1	$3.97M	Buy	43,500 +36,600	+530%	+$3M	﹤0.01%	1994
2018 Q4	$524K	Buy	+6,900	New	+$508K	﹤0.01%	4080

Citigroup's CBPO Position: Q2 2021 in Review

Citigroup sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 95,847 shares — an estimated $11.3M sold.

Citigroup first reported a position in CBPO in Q2 2013 and held it in 30 quarters. The position peaked at $11.3M in Q1 2021. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

Citigroup reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
Citigroup sold 95,847 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $11.3M.
Citigroup first reported a position in China Biologic Products Holdings, Inc. in Q2 2013 and held it in 30 quarters.
Citigroup's China Biologic Products Holdings, Inc. position peaked at $11.3M in Q1 2021.
0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.

Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.